Spyglass Capital Management LLC Has $57.45 Million Position in Ascendis Pharma A/S $ASND

Key Points

• Spyglass Capital Management cut its Ascendis Pharma position by 41.5% in the second quarter, selling 152,574 shares and retaining 215,398 shares valued at approximately $57.45 million.
• Analysts remain broadly bullish, with a consensus “Buy” rating and an average price target of $304.95; HC Wainwright initiated coverage with a $345 target, while Bank of America trimmed its target to $304 but maintained its Buy rating.
• Ascendis Pharma reported quarterly EPS of $1.03, below the $1.71 consensus estimate, though revenue of $387.22 million exceeded expectations. Director Jean Jacques Bienaime separately bought 2,000 shares worth approximately $492,660.

Spyglass Capital Management LLC lessened its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 41.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 215,398 shares of the biotechnology company's stock after selling 152,574 shares during the period. Ascendis Pharma A/S makes up about 3.1% of Spyglass Capital Management LLC's investment portfolio, making the stock its 20th biggest holding. Spyglass Capital Management LLC owned about 0.35% of Ascendis Pharma A/S worth $57,451,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Advisory Services Network LLC bought a new position in shares of Ascendis Pharma A/S during the third quarter worth $26,000. Arax Advisory Partners increased its position in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company's stock valued at $33,000 after buying an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth $42,000. Finally, Global Retirement Partners LLC lifted its holdings in Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company's stock worth $46,000 after acquiring an additional 113 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Bank of America decreased their target price on Ascendis Pharma A/S from $306.00 to $304.00 and set a "buy" rating for the company in a research note on Monday. HC Wainwright began coverage on Ascendis Pharma A/S in a report on Thursday. They set a "buy" rating and a $345.00 target price for the company. Morgan Stanley lifted their price target on Ascendis Pharma A/S from $256.00 to $275.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Evercore restated an "outperform" rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a report on Friday, May 15th. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $304.95.

Ascendis Pharma A/S Stock Up 6.1%

ASND stock opened at $263.04 on Tuesday. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average price of $256.44 and a two-hundred day moving average price of $239.47. The company has a market cap of $16.41 billion, a price-to-earnings ratio of 20.41 and a beta of 0.39. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The company had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Analysts anticipate that Ascendis Pharma A/S will post 3.9 EPS for the current fiscal year.

Key Stories Impacting Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis Pharma entered a binding term sheet with BioMarin Pharmaceutical for a global settlement and license agreement related to YUVIWEL (navepegritide). The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty and potentially improving the commercial outlook for the product. The market reacted favorably, with shares rising after the announcement. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL
• Positive Sentiment: Analysts continue to rate ASND positively. HC Wainwright maintained a Buy rating and a $345 price target, while Bank of America retained its Buy rating with a $304 target, both implying upside from the stock’s referenced $263.04 level. The stock also received an average Buy rating from covering analysts. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Neutral Sentiment: Bank of America trimmed its price target modestly from $306 to $304 while keeping a Buy rating, signaling slightly reduced valuation expectations but continued confidence in Ascendis Pharma’s prospects.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for every reported period from the third quarter of 2026 through the fourth quarter of 2027. Its FY2027 estimate fell to $11.25 from $11.88, while quarterly estimates were reduced by $0.07 to $0.19. These revisions indicate that the analyst expects somewhat slower near-term earnings growth, despite maintaining the Buy rating and $345 target.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, Director Jean Jacques Bienaime bought 2,000 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares of the company's stock, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 40.00% of the company's stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source